Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Economic and Social Standing of Individuals in Iran Diagnosed with Multiple Sclerosis.
Ghadiri F, Sahraian MA, Ashtari F, Baghbanian SM, Majdi-Nasab N, Hatamian H, Faraji F, Bayati A, Sharifipour E, Jalali N, Mozhdehipanah H, Kamali H, Ayoubi S, Eskandarieh S, Naser Moghadasi A. Ghadiri F, et al. Among authors: majdi nasab n. Arch Iran Med. 2023 Aug 1;26(8):413-418. doi: 10.34172/aim.2023.63. Arch Iran Med. 2023. PMID: 38301102 Free PMC article.
Diagnosis and management of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Iran: A consensus guideline and recommendations.
Sahraian MA, Moghadasi AN, Azimi AR, Asgari N, H Akhoundi F, Abolfazli R, Alaie S, Ashtari F, Ayromlou H, Baghbanian SM, Moghadam NB, Fatehi F, Foroughipour M, Langroodi HG, Majdinasab N, Nickseresht A, Nourian A, Shaygannejad V, Torabi HR. Sahraian MA, et al. Mult Scler Relat Disord. 2017 Nov;18:144-151. doi: 10.1016/j.msard.2017.09.015. Epub 2017 Sep 25. Mult Scler Relat Disord. 2017. PMID: 29141797 Review.
Primary progressive multiple sclerosis in Iran: A consensus recommendation for diagnosis and management.
Sahraian MA, Baghbanian SM, Langroodi HG, Abolfazli R, Alaie S, Asgari N, Ashtari F, Ayromlouh H, Moghadam NB, Foroughipour M, Majdinasab N, Mohammadianinejad SE, Nickseresht A, Nourian A, Shahmohammadi S, Shayegannejad V, Torabi HR. Sahraian MA, et al. Mult Scler Relat Disord. 2018 Nov;26:112-120. doi: 10.1016/j.msard.2018.09.013. Epub 2018 Sep 12. Mult Scler Relat Disord. 2018. PMID: 30245383 Review. No abstract available.
WITHDRAWN: Incidence and mortality of COVID-19 in Iranian multiple sclerosis patients treated with disease-modifying therapies.
Etemadifar M, Aghababaee A, Sedaghat N, Rayani M, Nouri H, Abhari A, Salari M, Majdinasab N, Ghiasian M, Bayati A, Nabavi SM, Mansouri A. Etemadifar M, et al. Rev Neurol (Paris). 2020 Sep 15:S0035-3787(20)30660-3. doi: 10.1016/j.neurol.2020.08.001. Online ahead of print. Rev Neurol (Paris). 2020. PMID: 33039152 Free PMC article.
Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study.
Doosti R, Naser Moghadasi A, Azimi AR, Karbalai Saleh S, Etemadifar M, Shaygannejad V, Ashtari F, Harirchian MH, Siroos SB, Ayramloo H, Majdinasab N, Hojjati SMM, Asghari N, Baghbanian SM, Cheraghmakani H, Abedini M, Sedighi B, Mohseni Abbas Abadi N, Ghasemitabar M, Talebianpour S, Babayi Daylari T, Dana V, Ghaleh Noie N, Sahraian MA. Doosti R, et al. Caspian J Intern Med. 2021 Apr;12(3):263-274. doi: 10.22088/cjim.12.3.263. Caspian J Intern Med. 2021. PMID: 34221275 Free PMC article.
57 results